brolucizumab-dbll

brolucizumab-dbll (BEOVU) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravitreal. Current US regulatory status: approved.

BEOVU is a marketed brand name for brolucizumab-dbll. Check FDA Drugs@FDA for the current US label holder and prescribing information.

brolucizumab-dbll has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.